Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Acoramidis PK in Healthy Volunteers
NCT04958135Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acoramidis in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of Acoramidis at 336 hours, Area Under the Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration for Acoramidis at 336 hours and 1 more. Started May 2021; status: completed.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04958135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958135.